Silence Therapeutics (SLN) Competitors $6.51 -0.23 (-3.41%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SLN vs. COLL, AVBP, AVDL, PAHC, NUVB, IMTX, IMNM, PSTX, ZYME, and PLRXShould you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include Collegium Pharmaceutical (COLL), ArriVent BioPharma (AVBP), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), Immatics (IMTX), Immunome (IMNM), Poseida Therapeutics (PSTX), Zymeworks (ZYME), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. Silence Therapeutics vs. Collegium Pharmaceutical ArriVent BioPharma Avadel Pharmaceuticals Phibro Animal Health Nuvation Bio Immatics Immunome Poseida Therapeutics Zymeworks Pliant Therapeutics Collegium Pharmaceutical (NASDAQ:COLL) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk & volatility, COLL or SLN? Collegium Pharmaceutical has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Do institutionals & insiders have more ownership in COLL or SLN? 98.7% of Silence Therapeutics shares are owned by institutional investors. 4.0% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better valuation & earnings, COLL or SLN? Collegium Pharmaceutical has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$599.25M1.66$48.15M$2.3213.32Silence Therapeutics$16.25M11.99-$53.82M-$1.57-4.15 Is COLL or SLN more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Silence Therapeutics' net margin of -342.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Silence Therapeutics -342.00%-62.81%-33.89% Does the MarketBeat Community favor COLL or SLN? Collegium Pharmaceutical received 346 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 81.25% of users gave Silence Therapeutics an outperform vote while only 65.25% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes38565.25% Underperform Votes20534.75% Silence TherapeuticsOutperform Votes3981.25% Underperform Votes918.75% Do analysts rate COLL or SLN? Collegium Pharmaceutical presently has a consensus target price of $42.60, suggesting a potential upside of 37.86%. Silence Therapeutics has a consensus target price of $57.20, suggesting a potential upside of 778.65%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to COLL or SLN? In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 3 mentions for Silence Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.63 beat Silence Therapeutics' score of 0.44 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCollegium Pharmaceutical beats Silence Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Banyan Hill PublishingTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLN vs. The Competition Export to ExcelMetricSilence TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.72M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-4.1510.79135.3117.54Price / Sales11.99287.861,215.74139.37Price / CashN/A56.6540.5837.95Price / Book9.175.394.884.92Net Income-$53.82M$152.04M$118.89M$225.78M7 Day Performance0.93%-4.32%16.99%-1.58%1 Month Performance-40.93%2.80%16.58%6.67%1 Year Performance-61.62%17.30%35.26%22.48% Silence Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNSilence Therapeutics3.6814 of 5 stars$6.51-3.4%$57.20+778.6%-59.4%$201.72M$16.25M-4.15100COLLCollegium Pharmaceutical3.9712 of 5 stars$30.99+3.4%$42.60+37.5%+4.3%$999.43M$566.77M12.92210News CoveragePositive NewsAVBPArriVent BioPharma1.1598 of 5 stars$28.52-2.5%$36.80+29.0%N/A$961.12MN/A0.0040Short Interest ↑Positive NewsAVDLAvadel Pharmaceuticals2.7809 of 5 stars$9.96-0.4%$24.43+145.3%-23.3%$959.75M$27.96M0.00154Short Interest ↑Positive NewsPAHCPhibro Animal Health4.1953 of 5 stars$23.55+1.5%$19.00-19.3%+97.9%$953.78M$1.02B53.981,940Analyst ForecastNews CoverageNUVBNuvation Bio1.9641 of 5 stars$2.83-0.7%$6.60+133.2%+99.6%$952.49MN/A-1.3160IMTXImmatics1.4359 of 5 stars$7.83-0.3%$16.67+112.9%-26.8%$934.59M$58.44M0.00260Short Interest ↑IMNMImmunome2.807 of 5 stars$14.82+7.9%$28.83+94.6%+59.4%$925.06M$14.02M-1.8440Short Interest ↓Positive NewsPSTXPoseida Therapeutics3.7029 of 5 stars$9.46+1.1%$9.50+0.4%+193.2%$922.02M$150.86M-14.81260ZYMEZymeworks3.0464 of 5 stars$13.36-6.2%$19.00+42.2%+46.9%$920.21M$62.20M-9.50290Analyst UpgradePositive NewsPLRXPliant Therapeutics3.3301 of 5 stars$14.98+2.0%$40.50+170.4%-14.3%$911.53M$1.58M0.0090 Related Companies and Tools Related Companies COLL Alternatives AVBP Alternatives AVDL Alternatives PAHC Alternatives NUVB Alternatives IMTX Alternatives IMNM Alternatives PSTX Alternatives ZYME Alternatives PLRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
